Related Experiment Video
Updated: Jun 16, 2025
05:25
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
19.1K
Is Canine Prostate-Specific Esterase a Reliable Marker for Benign Prostatic Hyperplasia Progression in Dogs?
Florin-Petrișor Posastiuc1,2, Nicolae-Tiberiu Constantin2, Guillaume Domain1
1Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Animals : an Open Access Journal From MDPI
|June 13, 2025
Summary
Canine prostate-specific esterase (CPSE) shows strong correlation with benign prostatic hyperplasia (BPH) severity and complexity in dogs. This biomarker aids in assessing BPH progression and related structural changes, offering valuable diagnostic insights.
Area of Science:
- Veterinary Medicine
- Canine Urology
- Biomarker Discovery
Background:
- Benign prostatic hyperplasia (BPH) is a prevalent condition in intact male dogs.
- BPH progresses from subclinical to symptomatic stages, impacting canine health.
- Accurate biomarkers are needed to assess BPH severity and progression.
Purpose of the Study:
- To evaluate canine prostate-specific esterase (CPSE) as a biomarker for BPH progression in dogs.
- To correlate CPSE levels with clinical severity, complexity, and ultrasonographic features of BPH.
Main Methods:
- Seventy-one dogs were categorized into subclinical-BPH, clinical-BPH, BPH-prostatitis, and control groups.
- Canine prostate-specific esterase (CPSE) levels were measured using a canine-specific ELISA.
- Statistical analyses, including correlation and logistic regression, were performed.
Main Results:
- CPSE levels significantly correlated with clinical severity (ρ = 0.800) and complexity (ρ = 0.818).
- CPSE effectively predicted mild and moderate BPH severity and low, moderate, and high clinical complexity.
- CPSE showed a trend towards predicting structural alterations and was associated with prostatic volume and cyst/abscess size.
Conclusions:
- Canine prostate-specific esterase (CPSE) is a promising biomarker for assessing benign prostatic hyperplasia progression in dogs.
- CPSE aids in quantifying clinical severity, complexity, and structural changes associated with canine BPH.
- This biomarker can improve diagnostic accuracy and management strategies for canine BPH.
